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a b s t r a c t
Background: The modern treatment of acute coronary syndromes includes early initiation of
dual antiplatelet therapy (DAPT) and coronary angiography (CAG) followed by percutaneous
coronary intervention (PCI) or coronary artery bypass grafting (CABG). Recently two new
potent antiplatelet agents (ticagrelor and prasugrel) were introduced in clinical practice. The
aim of this registry was to analyze the treatment strategies in two neighboring countries:
Czech (CZ) and Slovak (SK) Republics.
Patients and methods: A total of 1541 patients was enrolled during one month period in 18
tertiary cardiac centers in CZ (n = 1026) and 6 centers in SK (n = 515). The mean age was 66
 12 years (CZ) vs. 63  12 (SK), diabetes mellitus was present in 31.1% (CZ) and 32.6% (SK).
Prior revascularization was reported in 21.9% (CZ) vs. 16.1% (SK).
Results: ST-segment elevation myocardial infarction (STEMI) was the ﬁnal diagnosis in 51.9%
(CZ) vs. 44.9% (SK), non-STEMI in 34.1% vs. 31.3% and unstable angina pectoris (UAP) in 14.0%
vs. 23.9%. PCI during the initial hospital stay was performed in 83.4% (CZ) vs. 78.8% (SK). The
discharge medication included aspirin in 95.3% (both countries), clopidogrel in 75.3% (CZ) vs.
53.6% (SK), ticagrelor in 13.1% (CZ) vs. 17.3% (SK) and prasugrel in 2.6% (CZ) vs. 23.1% (SK).
Economic limits were reported to inﬂuence the choice of P2Y12 inhibitor in 36.9% (CZ) vs.
23.9% (SK).
The indication for ticagrelor was in STEMI 73.9% (CZ) vs. 36.0% (SK), non-STEMI in 20.9%
(CZ) vs. 40.4% (SK) and UAP in 5.2% (CZ) vs. 23.6% (SK). The indication for prasugrel was STEMI
in 81.5% (CZ) vs. 73.9% (SK), non-STEMI in 18.5% (CZ) vs. 11.8% (SK) and UAP in 0.0% (CZ) vs.
14.3% (SK).
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Conclusions: The baseline characteristics of ACS patients are similar in both countries, and
the Czech patients tend to be older and have more prior revascularizations.  Slovak patients
receive more often modern potent P2Y12 inhibitors. The results conﬁrm existing economic
barriers preventing full implementation of the antiplatelet recommendations from the
current ESC guidelines, but also lack of guidelines knowledge (or implementation) among
some physicians.
# 2014 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp. z o.o.
All rights reserved.
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.Table 1 – Baseline characteristics.
Parameter
N (%)/mean
(SD)
Czech Republic 
(population:
10.5 million)
N = 1026
Slovak
Republic
(population:
5.4 million)
N = 515
P
valuea
Females (%) 280 (27.3%) 144 (28.0%) 0.781
Mean age (years) 66  12 63  12 <0.001
Mean BMI 28.7  5.1 29.0  11.1 0.470
Hypertension 736 (71.7%) 403 (78.3%) 0.005
Current smokers 348 (33.9%) 143 (27.8%) 0.014
Diabetes mellitus 319 (31.1%) 168 (32.6%) 0.543
Prior myocardial 
infarction
212 (20.7%)  104 (20.2%)  0.830
Prior
revascularization
225 (21.9%) 83 (16.1%) 0.006
a Statistical significance of differences between groups was tested
by maximum likelihood chi-square test for categorical variables
and independent t-test for continuous variables.Introduction
The European Society of Cardiology (ESC) and the Czech/
Slovak Society of Cardiology guidelines [1–5] for treatment of
acute coronary syndromes (ACS) recommend the initiation of
dual antiplatelet therapy (DAPT) early after the diagnosis of an
acute coronary syndrome was established. Coronary angiog-
raphy (CAG) followed by percutaneous coronary intervention
(PCI) or coronary artery bypass grafting (CABG) should be
performed early, especially in the high risk patients.
The introduction of the high-sensitivity cardiac troponin
assays modiﬁed the spectrum of ACS in such ways, that
unstable angina is decreasing and non-STEMI rates are
increasing [6]. The widespread use of emergent CAG  PCI in
STEMI and in high risk non-STEMI led to a proposal to change
the classiﬁcation of acute coronary syndromes and to replace
the ECG-based classiﬁcation by an ongoing ischemia – base
classiﬁcation [7].
Recently two new potent antiplatelet agents (ticagrelor and
prasugrel) were introduced in clinical practice after two major
randomized trials proved their superiority over clopidogrel
[8,9]. The aim of this registry was to analyze the treatment
strategies in two neighbor countries: Czech and Slovak
republics.
Patients and methods
All consecutive patients, who were discharged home or
transferred to other hospital from PCI centers in the Czech
and Slovak republics during one month (in 2013), were the
subjects of the observation. Dataset was collected in electronic
clinical data management system, which is originally based on
a modiﬁed version of TrialDB system [10]. This on-line system,
widely accessible via a standard Internet browser, was
customized for the collection of speciﬁc clinical data of the
current study. Control mechanisms were added to improve
quality of data.
Standard descriptive statistics were applied in the analysis;
absolute and relative frequencies for categorical variables and
mean supplemented by standard deviation for continuous
variables. Statistical signiﬁcance of differences between
groups of patients was tested using maximum likelihood
chi-square test and independent t-test for continuous vari-
ables. Analysis was computed using SPSS 22 (IBM Corporation,
2013).A total of 1541 patients were enrolled during one month
period in 18 tertiary cardiac centers in the Czech Republic
(n = 1026) and 6 centers in the Slovak Republic (n = 515). The
comparison of baseline characteristics is given in Table 1.
Results
The main results of the registry are given in Table 2. ST-
segment elevation myocardial infarction (STEMI) was the ﬁnal
diagnosis in 51.9% (CZ) vs. 44.9% (SK), non-STEMI in 34.1% vs.
31.3% and unstable angina pectoris (UAP) in 14.0% vs. 23.9%.
PCI during the initial hospital stay was performed in 83.4% (CZ)
vs. 78.8% (SK). The discharge medication included aspirin in
95.3% (both countries), clopidogrel in 75.3% (CZ) vs. 53.6% (SK),
ticagrelor in 13.1% (CZ) vs. 17.3% (SK) and prasugrel in 2.6% (CZ)
vs. 23.1% (SK). Economic limits were reported to inﬂuence the
choice of P2Y12 inhibitor in 36.9% (CZ) vs. 23.9% (SK).
The indication for ticagrelor was in STEMI 73.9% (CZ) vs.
36.0% (SK), non-STEMI in 20.9% (CZ) vs. 40.4% (SK) and UAP in
5.2% (CZ) vs. 23.6% (SK). The indication for prasugrel was STEMI
in 81.5% (CZ) vs. 73.9% (SK), non-STEMI in 18.5% (CZ) vs. 11.8%
(SK) and UAP in 0.0% (CZ) vs. 14.3% (SK).
Table 2 – Main results of the registry.
Parameter
N (%)
Czech Republic
N = 1026
Slovak Republic
N = 515
P valuea
STEMI as ﬁnal diagnosis 532 (51.9%) 231 (44.9%) <0.001
Non-STEMI as ﬁnal diagnosis 350 (34.1%) 161 (31.3%)
Unstable angina as ﬁnal diagnosis 144 (14.0%) 123 (23.9%)
ACS treated by PCI 856 (83.4%) 406 (78.8%) 0.029
ASA prescribed at discharge 978 (95.3%) 492 (95.5%) 0.851
Clopidogrel prescribed at discharge 773 (75.3%) 276 (53.6%) <0.001
Ticagrelor prescribed at discharge 134 (13.1%) 89 (17.3%) 0.028
Prasugrel prescribed at discharge 27 (2.6%) 119 (23.1%) <0.001
Prehospital (during transport)
initiation of DAPT
470 (60.9%) 343 (87.7%) <0.001
Economic limits caused clopidogrel
prescription (rather than more
potent P2Y12 inhibitors)
379 (36.9%) 123 (23.9%) <0.001
a Statistical significance of differences between groups was tested by maximum likelihood chi-square test for categorical variables and
independent t-test for continuous variables.
Table 3 – Economic conditions for the use of the novel
antiplatelet drugs.
Czech
Republic
Slovak
Republic
Clopidogrel total price 14.12s 4.11s
Clopidogrel reimbursement +
price for the patient
14.12s + 0 3.58s + 0.53s
Prasugrel total price 52.55s 51.25s
Prasugrel reimbursement +
price for the patient
14.12s + 38.43s 38.58s + 12.67s
Ticagrelor total price 78.14s 72.72s
Ticagrelor reimbursement +
price for the patient
14.12s + 64.02s 40.90s/31.82s
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 3 2 0 – e 3 2 4e322Discussion
Published registries on acute coronary syndromes are usually
focused on patients' outcomes and general information about
treatment strategies, but only limited information about the
details of antiplatelet therapy is provided. No such information
was available from the Czech and Slovak republics. ATHRO is
the ﬁrst systematic evaluation of antiplatelet therapy in acute
coronary syndromes in both participating countries.
The ATHRO registry in comparison with SLOVAKS-2 registry
[11] and the Slovak Society of Cardiology guidelines showed
increased use of the novel antiplatelets agents ticagrelor and
prasugrel in patients with ACS in the Slovak Republic. Ticagrelor
was not used in patients enrolled to the SLOVAKS-2 registry, but
was used in 17.3% of ACS patients in ATHRO. Similarly, the use
of prasugrel in STEMI increased from 6.6% (SLOVAKS-2) to 23.1%
(ATHRO). These trends are reﬂecting the improved implemen-
tation of the latest guidelines [1–5].
Despite the economic barriers, the use of the novel
antiplatelet agents signiﬁcantly increased (40.4% at discharge)
in Slovakia during 2013, but the existing prescription limita-
tions and suboptimal guidelines implementation remain to
cause less than ideal use of these agents in everyday practice.
The advantages of ticagrelor include its proven efﬁcacy in
patients pretreated with clopidogrel and in patients treatedwithout PCI (i.e. medically or surgically). Prasugrel main
advantage is its proven efﬁcacy in patients receiving stents,
especially for acute STEMI.
The CZECH-2 registry [12] demonstrated that on admission
the following medications are used by the patients: 39.8%
aspirin; 7.6% clopidogrel and 8.7% oral anticoagulants. At
discharge, the following medications were administered: aspirin
93.5%; clopidogrel 76.4%; prasugrel 0.6%; ticagrelor 0.8%; oral
anticoagulation 9.5%. ATHRO showed also positive trends in the
Czech Republic, but to a lesser degree than in Slovakia.
As the economic and/or prescribing (indication) limits play a
major role in the selection of P2Y12 inhibitor by a physician for a
given patient, we provide detailed information on this topic in
Table 3. This table clearly explains the differences in novel
antiplatelet drug use: prasugrel is three times more expensive
for the Czech patients than for their Slovak counterparts and
ticagrelor is twice more expensive for the Czech patients. This is
an indirect conﬁrmation of the well known fact, that the drug
price for the patient (how much he/she has to pay in the
pharmacy) is the most important driver of treatment selection.
Generally in Czech and Slovak republics the indication for
prasugrel in non-STE ACS was not yet inﬂuenced by publica-
tions of the TRILOGY ACS trial results [13].
Conclusions
The baseline characteristics of ACS patients are similar in both
countries, and the Czech patients tend to be older and have
more prior revascularizations. Slovak patients receive more
often modern potent P2Y12 inhibitors. The results conﬁrm
existing economic barriers preventing full implementation of
the antiplatelet recommendations from the current ESC
guidelines, but also lack of guidelines knowledge (or imple-
mentation) among some physicians.
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